"The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach./"...
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
CARBOPLATIN - INJECTION
COMMON BRAND NAME(S): Paraplatin
WARNING: Carboplatin can cause severe blood disorders (e.g., anemia, bone marrow suppression) that can result in infection and bleeding problems. Your risk of developing these problems increases with higher doses or longer treatment with carboplatin. Also, an unlikely but very serious allergic reaction to this drug may occur within minutes of receiving a dose. Tell your doctor immediately if you develop any of the following symptoms: easy bruising/bleeding, signs of infection (e.g., persistent sore throat, fever), unusual tiredness, rash, itching, swelling, severe dizziness, or trouble breathing.
Vomiting is a common side effect of this medication. See the Side Effects section for more information.
USES: Carboplatin is used to treat various types of cancer. It is a chemotherapy drug that contains platinum. It is used alone or in combination with other medications to slow or stop cancer cell growth.
HOW TO USE: Carboplatin is usually given by infusion into a vein (intravenously-IV) over at least 15 minutes by a healthcare professional.
The dosage is based on your medical condition, body size, and response to therapy. In general, courses of carboplatin treatment should not be given more often than once every 4 weeks. Consult your doctor or pharmacist for more details.
Additional Paraplatin Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.